LARGON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 12h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARGON is an injectable NDA-approved product developed by Hikma with an unknown mechanism of action and indication profile. As a legacy injectable medication approved in 1960, it represents a mature therapeutic asset with limited available clinical documentation in modern databases.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100) and minimal recent hiring activity suggests cost management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and LOE-approaching lifecycle indicate this product is not actively recruiting. Working on LARGON would be appropriate for early-career professionals seeking to manage brand decline, understand commercial lifecycle management, or transition to higher-growth assets.
Brand ManagerSales Representative
Worked on LARGON at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.